摘要
目的:探讨索拉非尼在中晚期肝细胞肝癌联合治疗中的临床价值。方法:回顾性分析21例口服索拉非尼的中晚期肝细胞肝癌患者的临床资料,其中12例患者单纯行经肝动脉化疗栓塞术(TACE)治疗,2例患者行超声聚焦刀和生物治疗,4例患者行TACE结合微波消融治疗,3例患者行TACE、微波消融和生物综合治疗。结果:21例患者中完全缓解(CR)2例(9.5%),部分缓解(PR)3例(14.3%),疾病稳定(SD)10例(47.6%),疾病进展(PD)6例(28.6%),临床获益率(CBR)为71.4%。结论:索拉非尼在中晚期肝细胞肝癌综合治疗中明显提高患者临床获益率,延长肿瘤进展时间。
Objective：To investigate the clinical value of sorafenib in combination treatment for advanced hepatocellular carcinoma. Methods：21 advanced hepatocellular carcinoma patients receiving sorafenib were retrospectively analyzed, in which 12 patients were only treated with transcatheter arterial chemoembolization（TACE）, 2 patients were treated with biotherapy and high intensity focused ultrasound, 4 patients were treated with TACE and radio frequency current ablation, 3 patients were treated with TACE, biotherapy and radio frequency current ablation. Results：2 patients achieved a complete response （CR 9.5%）, 3 patients achieved a partial response （PR 14.3%）, 10 patients had stable disease （SD 47.6%）, 6 patients had progressive disease （PD 28.6%）, and clinical benefit rate （CBR） was 71.4%. Conclusion：Sorafenib in combination treatment for advanced hepatocellular carcinoma can increase clinical benefit rate and prolong the time to tumor progression.
出处
《东南大学学报（医学版）》
CAS
北大核心
2016年第1期106-108,共3页
Journal of Southeast University(Medical Science Edition)
关键词
肝细胞肝癌
索拉非尼
经肝动脉化疗栓塞术
hepatocellular carcinoma
sorafenib
transcatheter arterial chemoembolization
